ClinicalTrials.Veeva

Menu

Evaluation of Metabolic Activity of Liver Metastases by FDG-PET Scanning

R

Radboud University Medical Center

Status

Unknown

Conditions

Colorectal Neoplasms

Treatments

Procedure: FDG-PET

Study type

Interventional

Funder types

Other

Identifiers

NCT00184782
CP 2005

Details and patient eligibility

About

The purpose of this study is to evaluate the effect of primary tumor resection on the metabolic activity of metastases in patients with a colorectal primary tumor and synchronous liver metastases by positron emission tomography (PET) with 2-deoxy-2-fluoro[18F]-D-glucose (FDG-PET) scanning.

Full description

The goal of this study is to evaluate the activity of liver metastases before and after resection of the primary tumor. Non-invasive assessment of tumor metabolism is possible in vivo by means of positron emission tomography (PET)-scanning. Therefore, FDG-PET scan offers a suitable approach to determine the influence of removal of a primary colorectal tumor on metabolic activity of the liver metastases. The FDG uptake in the liver metastases is quantified by calculating standardised uptake values (SUVs).

Enrollment

30 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Colorectal cancer and synchronous liver metastases

Exclusion criteria

  • Pregnancy

Trial design

Primary purpose

Diagnostic

Allocation

Non-Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

Trial contacts and locations

1

Loading...

Central trial contact

Charlotte Peeters, MD; Theo Ruers, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems